Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin K studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin KVitamin K (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Vitamin K2 Supplementation in Hospitalised COVID-19 Patients: A Randomised Controlled Trial

Visser et al., Journal of Clinical Medicine, doi:10.3390/jcm13123476, KOVIT, NCT04770740
Jun 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -200% Improvement Relative Risk ICU admission -200% Hospitalization time 17% Vitamin K  KOVIT  LATE TREATMENT  DB RCT Is late treatment with vitamin K beneficial for COVID-19? Double-blind RCT 40 patients in Netherlands Shorter hospitalization with vitamin K (not stat. sig., p=0.52) c19early.org Visser et al., J. Clinical Medicine, Jun 2024 Favorsvitamin K Favorscontrol 0 0.5 1 1.5 2+
RCT 40 hospitalized COVID-19 patients showing vitamin K2 supplementation was well-tolerated and reduced dp-ucMGP levels, reflecting improved vitamin K status, but did not affect desmosine, a marker of elastic fiber degradation. The study was not powered to assess effects on clinical outcomes. Authors suggest that the dose may have been insufficient to fully correct the vitamin K deficiency seen in COVID-19, and that higher doses might be required to achieve potential protective effects against inflammation or lung damage.
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 20 (5.0%), control 0 of 20 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 200.0% higher, RR 3.00, p = 0.60, treatment 3 of 20 (15.0%), control 1 of 20 (5.0%).
hospitalization time, 16.7% lower, relative time 0.83, p = 0.52, treatment median 5.0 IQR 6.0 n=20, control median 6.0 IQR 7.0 n=20.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Visser et al., 14 Jun 2024, Double Blind Randomized Controlled Trial, placebo-controlled, Netherlands, peer-reviewed, 10 authors, trial NCT04770740 (history) (KOVIT).
This PaperVitamin KAll
Vitamin K2 Supplementation in Hospitalised COVID-19 Patients: A Randomised Controlled Trial
Margot P J Visser, Anton S M Dofferhoff, Jody M W Va Den Ouwelan, Pim A De Jong, Piet Zanen, Henny Van Daal, Eline B Theeuwen, Cornelis Kramers, Rob Janssen, Jona Walk
doi:10.3390/jcm13123476
Background: In observational studies, high levels of desphospho-uncarboxylated matrix gla protein (dp-ucMGP) that result from vitamin K deficiency were consistently associated with poor clinical outcomes during COVID-19. Vitamin K-activated matrix gla protein (MGP) is required to protect against elastic fibre degradation, and a deficiency may contribute to pathology. However, intervention trials assessing the effects of vitamin K supplementation in COVID-19 are lacking. Methods: This is a single-centre, phase 2, double-blind, randomised, placebo-controlled trial investigating the effects of vitamin K2 supplementation in 40 hospitalised COVID-19 patients requiring supplemental oxygen. Individuals were randomly assigned in a 1:1 ratio to receive 999 mcg of vitamin K2-menaquinone-7 (MK-7)-or a placebo daily until discharge or for a maximum of 14 days. Dp-ucMGP, the rate of elastic fibre degradation quantified by desmosine, and hepatic vitamin K status quantified by PIVKA-II were measured. Grade 3 and 4 adverse events were collected daily. As an exploratory objective, circulating vitamin K2 levels were measured. Results: Vitamin K2 was well tolerated and did not increase the number of adverse events. A linear mixed model analysis showed that dp-ucMGP and PIVKA-II decreased significantly in subjects that received supplementation compared to the controls (p = 0.008 and p = 0.0017, respectively), reflecting improved vitamin K status. The decrease in dp-ucMGP correlated with higher plasma MK-7 levels (p = 0.015). No significant effect on desmosine was found (p = 0.545). Conclusions: These results demonstrate that vitamin K2 supplementation during COVID-19 is safe and decreases dp-ucMGP. However, the current dose of vitamin K2 failed to show a protective effect against elastic fibre degradation.
Institutional Review Board Statement: The study was approved by the ethical review board CMO Arnhem-Nijmegen on the 15th of February 2021 (NL74583.091.20). The local review committee of the Canisius-Wilhelmina Hospital approved the protocol (CWZ-nr. 107-2021). This trial is registered at ClinicalTrials.gov, identifier NCT04770740. Informed Consent Statement: Informed consent was obtained from all 40 participants involved in the study. Conflicts of Interest: R.J. discloses the application of a patent on vitamin K in COVID-19 that is held by Emphysema Solutions Bv of which R.J. and J.W. are owners. M.P.J.V., J.W., R.J. and A.S.M.D. had a scientific collaboration with Kappa Bioscience A.S., which is a manufacturer of vitamin K2 (MK-7). R.J. and J.M.W.O. are owners of Desmosine.com. H.D., P.A.J., P.Z., E.B.T. and C.K. declare no competing interests. Abbreviations COVID-19: Coronavirus Disease 2019; dp-uc, desphospho-uncarboxylated; MGP, matrix gla protein; SARS-CoV, severe acute respiratory syndrome coronavirus; MK-7, menaquinone-7; PIVKA-II, protein induced by vitamin K absence or antagonist-II; PCR, Polymerase Chain Reaction; LMWH, low-molecular-weight heparin; eCRF, electronic Case Report Form; SMC, Safety Monitoring Committee; IL-6, interleukin-6; CT, Computed Tomography; LC-MS/MS, liquid chromatography with tandem mass spectrometry; ITT, intention to treat; AIC, Akaike's Information Criterion; BMI, Body Mass Index; ICU, Intensive Care Unit.
References
Akbulut, Pavlic, Petsophonsakul, Halder, Maresz et al., Vitamin k2 needs an RDI separate from vitamin k1, Nutrients, doi:10.3390/nu12061852
Anastasi, Ialongo, Labriola, Ferraguti, Lucarelli et al., Vitamin k deficiency and COVID-19, Scand. J. Clin. Lab. Investig, doi:10.1080/00365513.2020.1805122
Booth, Martini, Peterson, Saltzman, Dallal et al., Dietary phylloquinone depletion and repletion in older women, J. Nutr, doi:10.1093/jn/133.8.2565
Burstyn-Cohen, Heeb, Lemke, Lack of protein s in mice causes embryonic lethal coagulopathy and vascular dysgenesis, J. Clin. Investig, doi:10.1172/JCI39325
Cho, Lee, Sia, Koo, Tan et al., Extrapulmonary manifestations and complications of severe acute respiratory syndrome coronavirus-2 infection: A systematic review, Singap. Med. J, doi:10.11622/smedj.2021100
Cranenburg, Koos, Schurgers, Magdeleyns, Schoonbrood et al., Characterisation and potential diagnostic value of circulating matrix GLA protein (MGP) species, Thromb. Haemost, doi:10.1160/TH09-11-0786
Cui, Chen, Li, Liu, Wang, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J. Thromb. Haemost, doi:10.1111/jth.14830
De Vriese, Caluwé, Pyfferoen, De Bacquer, De Boeck et al., Multicenter randomized controlled trial of vitamin k antagonist replacement by rivaroxaban with or without vitamin k2 in hemodialysis patients with atrial fibrillation: The valkyrie study, J. Am. Soc. Nephrol, doi:10.1681/ASN.2019060579
Desai, Dirajlal-Fargo, Durieux, Tribout, Labbato et al., Vitamin k & d deficiencies are independently associated with COVID-19 disease severity, Open Forum Infect. Dis
Dofferhoff, Piscaer, Schurgers, Visser, Van Den Ouweland et al., Reduced vitamin k status as a potentially modifiable risk factor of severe COVID-19, Clin. Infect. Dis, doi:10.1093/cid/ciaa1258
Huang, Bolton, Miller, Tal-Singer, Rabinovich et al., Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease, Eur. Respir. J, doi:10.1183/13993003.01125-2016
Irwin, Adie, Sandison, Alsomairy, Brancaccio, Warfarin dose requirements in adults hospitalized with COVID-19 infection: A retrospective case series, J. Pharm. Pract, doi:10.1177/08971900211000705
Jaminon, Dai, Qureshi, Evenepoel, Ripsweden et al., Matrix GLA protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease, Sci. Rep, doi:10.1038/s41598-020-63013-8
Janssen, Vermeer, Vitamin k deficit and elastolysis theory in pulmonary elasto-degenerative diseases, Med. Hypotheses, doi:10.1016/j.mehy.2017.07.029
Kumric, Borovac, Ticinovic Kurir, Martinovic, Frka Separovic et al., Role of matrix GLA protein in the complex network of coronary artery disease: A comprehensive review, Life, doi:10.3390/life11080737
Leisman, Ronner, Pinotti, Taylor, Sinha et al., Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes, Lancet Respir. Med, doi:10.1016/S2213-2600(20)30404-5
Linneberg, Kampmann, Israelsen, Andersen, Jørgensen et al., The association of low vitamin k status with mortality in a cohort of 138 hospitalized patients with COVID-19, Nutrients, doi:10.3390/nu13061985
Luo, Ducy, Mckee, Pinero, Loyer et al., Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein, Nature, doi:10.1038/386078a0
Ma, Lin, Turino, Measurements of desmosine and isodesmosine by mass spectrometry in COPD, Chest, doi:10.1378/chest.06-2251
Ma, Turino, Hayashi, Yanuma, Usuki et al., Stable deuterium internal standard for the isotope-dilution lc-ms/ms analysis of elastin degradation, Anal. Biochem, doi:10.1016/j.ab.2013.05.014
Majumder, Nguyen, Protein s: Function, regulation, and clinical perspectives, Curr. Opin. Hematol, doi:10.1097/MOH.0000000000000663
Mangge, Prueller, Dawczynski, Curcic, Sloup et al., Dramatic decrease of vitamin k2 subtype menaquinone-7 in COVID-19 patients, Antioxidants, doi:10.3390/antiox11071235
Mccann, Ames, Vitamin k, an example of triage theory: Is micronutrient inadequacy linked to diseases of aging?, Am. J. Clin. Nutr, doi:10.3945/ajcn.2009.27930
Mitsui, Effect of natto including bacillus subtilis k-2 (spore) on defecation and fecal microbiota and safety of excessive ingestion in healthy volunteers, Jpn. Pharmacol. Ther
Molfino, Anastasi, Assanto, Toccini, Imbimbo et al., Association between serum levels of GDF-15, SUPAR, PIVKA-ii, SDLDL and clinical outcomes in hospitalized COVID-19 patients, Intern. Emerg. Med, doi:10.1007/s11739-024-03630-7
Mulder, Schellens, Sels, Van Rosmalen, Hulshof et al., Higher levels of circulating desphospho-uncarboxylated matrix GLA protein over time are associated with worse survival: The prospective maastricht intensive care covid cohort, J. Intensive Care, doi:10.1186/s40560-023-00712-0
Padda, Patel, Citla Sridhar, Protein, Statpearls, None
Piscaer, Janssen, Franssen, Schurgers, Wouters, The pleiotropic role of vitamin k in multimorbidity of chronic obstructive pulmonary disease, J. Clin. Med, doi:10.3390/jcm12041261
Popa, Bigman, Rusu, The role of vitamin k in humans: Implication in aging and age-associated diseases, Antioxidants, doi:10.3390/antiox10040566
Proskuriakova, Jasaraj, Shrestha, Reddy, Khosla, Acute portal vein thrombosis as an initial presentation of protein c deficiency: A case report, Cureus, doi:10.7759/cureus.40407
Rucker, Calcium binding to elastin, Adv. Exp. Med. Biol
Speed, Patel, Byrne, Roberts, Arya, A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin k antagonists during the COVID-19 pandemic, Thromb. Res, doi:10.1016/j.thromres.2020.05.024
Staufer, Gupta, Hernandez Bücher, Kohler, Sigl et al., Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein, Nat. Commun, doi:10.1038/s41467-022-28446-x
Sumi, Accumulation of vitamin k (menaquinone-7) in plasma after ingestion of natto and natto bacilli (B. subtilis natto), Food Sci. Technol. Res, doi:10.3136/fstr.5.48
Suttie, Vitamin k-dependent carboxylase, Annu. Rev. Biochem, doi:10.1146/annurev.bi.54.070185.002331
Tsukamoto, Ichise, Kakuda, Yamaguchi, Intake of fermented soybean (natto) increases circulating vitamin k2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals, J. Bone Miner. Metab, doi:10.1007/s007740070023
Turck, Bresson, Burlingame, Dean, Fairweather-Tait et al., Dietary reference values for vitamin k, Efsa J
Visser, Dofferhoff, Van Den Ouweland, Van Daal, Kramers et al., Effects of vitamin d and k on interleukin-6 in COVID-19, Front. Nutr, doi:10.3389/fnut.2021.761191
Visser, Walk, Vermeer, Bílková, Janssen et al., Enhanced vitamin k expenditure as a major contributor to vitamin k deficiency in COVID-19, Int. J. Infect. Dis, doi:10.1016/j.ijid.2022.10.030
Yamaguchi, Kakuda, Gao, Tsukamoto, Prolonged intake of fermented soybean (natto) diets containing vitamin k2 (menaquinone-7) prevents bone loss in ovariectomized rats, J. Bone Miner. Metab, doi:10.1007/s007740050014
Zhan, Zha, Lin, Mao, Yang et al., Protective role of vitamin k3 on SARS-CoV-2 structural protein-induced inflammation and cell death, Pharmaceuticals, doi:10.3390/ph16081101
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit